RANDOM PROSPECTIVE-STUDY OF CYCLOPHOSPHAMIDE, DOXORUBICIN, AND METHOTREXATE (CAM) COMBINATION CHEMOTHERAPY VERSUS SINGLE-AGENT SEQUENTIAL CHEMOTHERAPY IN NON-SMALL CELL LUNG-CANCER
- 1 January 1982
- journal article
- research article
- Vol. 66 (12) , 2005-2011
Abstract
A group of 104 patients with unresectable non-small cell lung cancer were randomized to receive combination chemotherapy with cyclophosphamide, doxorubicin and methotrexate (CAM) or single-agent sequential chemotherapy with the same 3 agents. CAM combination chemotherapy produced a 22% objective response rate, including 2 complete remissions, compared to a 9% response rate, including 1 complete remission, produced by single-agent therapy (P = 0.16). The median survival time was 32 wk (range, 3-116) for CAM, compared to 25 wk (range, 4-179+) for sequential single agents (P = 0.24). Overall survival was 31% (1-yr), 16% (1 1/2-yr) and 5% (2-yr), with no difference between the study arms. Although there was no statistically significant survival advantage for the CAM arm, both arms had survival superior to that in historical controls, presumably because of better patient selection. Cyclophosphamide, doxorubicin and methotrexate apparently are, at best, marginally active as single agents. New drugs with more efficacy are needed before combination chemotherapy can be expected to result in any meaningful prolongation of survival in non-small cell lung cancer.This publication has 12 references indexed in Scilit:
- Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage SchedulesAnnals of Internal Medicine, 1981
- MACC chemotherapy for adenocarcinoma and epidermoid carcinoma of the lung.Low response rate in a cooperative group studyCancer, 1979
- MACC (methotrexate, adriamycin, cyclophosphamide and CCNU) in advanced lung cancerCancer, 1979
- PHASE-II EVALUATION OF VINDESINE IN PATIENTS WITH NON-SMALL CELL-CARCINOMA OF THE LUNG1979
- Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP)JAMA, 1978
- Chemotherapy for Bronchogenic CarcinomaJAMA, 1977
- Therapy of advanced squamous carcinoma of the lung.Cyclophosphamide versus “COMB”Cancer, 1977
- PLATINUM-BASED POLYCHEMOTHERAPY VERSUS DIANHYDROGALACTITOL IN ADVANCED NON-SMALL CELL LUNG-CANCER1977
- Bacon (bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard) in squamous lung cancer. Experience in fifty patientsCancer, 1976
- CYCLOPHOSPHAMIDE, ADRIAMYCIN, METHOTREXATE, AND PROCARBAZINE (CAMP)-EFFECTIVE 4-DRUG COMBINATION CHEMOTHERAPY FOR METASTATIC NON-OAT CELL BRONCHOGENIC CARCINOMA1976